Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN: Apabetalone in Dyslipidemia with Low HDL-C
NCT01423188Phase 2Completed
- Sponsor
- Resverlogix Corp.
- Start
- Aug 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apabetalone in dyslipidemia, coronary artery disease (CAD), sponsored by Resverlogix Corp.. Started Aug 2011; status: completed.
02
Drugs
apabetalone
03
Conditions
dyslipidemiacoronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01423188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01423188.